A little known biotech called Strongbridge Biopharma has attracted the attention of a prominent US senator who would like to make the company the latest poster child for price gouging in the pharma world.
Earlier this week the Washington Post published a report which detailed how Strongbridge obtained an old and once cheap drug that had nabbed an FDA approval for a rare disease, and jacked a six-figure price for patients. And Missouri Senator Claire McCaskill says she wants to do something to stop this — and prevent others from following what has become a well worn path.
Sixteen years ago, the Post reported, you could buy 100 pills of Daranide for $50 and use it to treat glaucoma. It also became popular among a small group of patients suffering from periodic paralysis. And when Merck dropped the drug, those rare disease patients began to source the treatment from overseas for a few hundred dollars a month.
Taro then got the drug rights from Merck in 2008 — inspired by the son of the chairman, who suffered from periodic paralysis — but then was acquired by Sun. The rare disease approval came through in 2015, the name changed to Keveyis and the price went to $13,650 for 100 pills. Then Strongbridge nabbed the 50-year-old drug and drove the price to $15,001 for 100 pills.
The cost for treating a patient with the drug: $109,500 to $219,000 a year, depending on the dose.
The strategy is similar to what Marathon did when it bagged rights to a cheap European steroid and then won an FDA approval to sell it for Duchenne muscular dystrophy after dusting off some old data from a long forgotten study. In the subsequent controversy that erupted when they announced a price of $89,000 a year, Marathon sold the drug to PTC Therapeutics.
Martin Shkreli, now in prison awaiting sentencing on a fraud conviction, still draws criticism for his move to buy an old and closely controlled therapy and then simply hiked the price more than 5,000%.
“Time and again we’ve seen pharmaceutical companies acquire decades old prescription drugs and gouge consumers—and it’s time we explored every possible way to prevent this practice,” McCaskill said in a statement.
McCaskill, though, isn’t the only politician to condemn such price spikes. But as PTC, Turing and others have shown, even the sharpest criticism in Washington DC can do little to rein in a drug’s price, when the law gives manufacturers free rein to set whatever price they please.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 28,000+ biopharma pros who read Endpoints News by email every day.Free Subscription